EMBL Ventures

Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological capabilities. Its lead product candidate, TPM203, is currently undergoing clinical testing for pemphigus vulgaris, an orphan disease. Additional programs are being developed for conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. Topas Therapeutics has established research and collaboration agreements with notable partners, including Eli Lilly and Company and Boehringer Ingelheim, to advance its innovative approaches to immune tolerance. The company aims to address significant unmet medical needs by promoting immune tolerance to blood-borne antigens.

Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological capabilities. Its lead product candidate, TPM203, is currently undergoing clinical testing for pemphigus vulgaris, an orphan disease. Additional programs are being developed for conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. Topas Therapeutics has established research and collaboration agreements with notable partners, including Eli Lilly and Company and Boehringer Ingelheim, to advance its innovative approaches to immune tolerance. The company aims to address significant unmet medical needs by promoting immune tolerance to blood-borne antigens.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

Luxendo specializes in the development and manufacture of advanced light-sheet fluorescence microscopy instruments, specifically Single Plane Illumination Microscopes (SPIM). Originally developed at the European Molecular Biology Laboratory by Lars Hufnagel and his team, the SPIM technology offers a novel approach to bio-imaging by combining optical sectioning with multiple-view imaging. This technique allows for rapid three-dimensional imaging of living specimens, such as spheroids and whole organisms, without the need for sample rotation. The design prioritizes gentle handling, making it suitable for delicate cell cultures and developing embryonic samples. As a result, Luxendo's instruments enable scientists to observe living organisms over extended periods without causing photo damage, thereby enhancing research capabilities in various biological fields.

Allecra Therapeutics, a clinical stage biopharmaceutical company, was established in 2013 and is dedicated to the development of novel treatments to combat multi drug-resistant bacterial infections. Allecra has a novel β-lactamase inhibitor in Phase 2 clinical development. By inhibiting β-lactamases Allecra’s new medicine directly tackles emerging resistance mechanisms of certain hard-to-treat bacteria. These resistance mechanisms are often found in hospital-acquired Gram-negative bacterial infections, and are of particular concern to doctors, healthcare providers, to patients and their families and to governments around the world. Allecra Therapeutics is situated in the BioValley Life Sciences region in the Upper Rhein valley whichencompasses northwest Switzerland, southwestern Germany and the Alsace region of France

Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological capabilities. Its lead product candidate, TPM203, is currently undergoing clinical testing for pemphigus vulgaris, an orphan disease. Additional programs are being developed for conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. Topas Therapeutics has established research and collaboration agreements with notable partners, including Eli Lilly and Company and Boehringer Ingelheim, to advance its innovative approaches to immune tolerance. The company aims to address significant unmet medical needs by promoting immune tolerance to blood-borne antigens.

Luxendo specializes in the development and manufacture of advanced light-sheet fluorescence microscopy instruments, specifically Single Plane Illumination Microscopes (SPIM). Originally developed at the European Molecular Biology Laboratory by Lars Hufnagel and his team, the SPIM technology offers a novel approach to bio-imaging by combining optical sectioning with multiple-view imaging. This technique allows for rapid three-dimensional imaging of living specimens, such as spheroids and whole organisms, without the need for sample rotation. The design prioritizes gentle handling, making it suitable for delicate cell cultures and developing embryonic samples. As a result, Luxendo's instruments enable scientists to observe living organisms over extended periods without causing photo damage, thereby enhancing research capabilities in various biological fields.

ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients.

ImevaX is a biopharmaceutical company founded in 2014 based in Munich, Germany. The focus is to combat chronic and nosocomial infections by creating specific vaccines. The company’s lead candidate IMX 101 is a vaccine against Helicobacter pylori, which colonizes the stomach and is the cause of ulcer disease and gastric cancer in humans. Founder Markus Gerhard and his team discovered that the colonization ability (and hence, the infectiousness) of H. pylori depends on a secreted bacterial factor that down-regulates the host immune system. Many other highly infectious pathogens have evolved similar immune evasion mechanisms, which are the focus of the ImevaX screening program.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.

Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.

Allecra Therapeutics, a clinical stage biopharmaceutical company, was established in 2013 and is dedicated to the development of novel treatments to combat multi drug-resistant bacterial infections. Allecra has a novel β-lactamase inhibitor in Phase 2 clinical development. By inhibiting β-lactamases Allecra’s new medicine directly tackles emerging resistance mechanisms of certain hard-to-treat bacteria. These resistance mechanisms are often found in hospital-acquired Gram-negative bacterial infections, and are of particular concern to doctors, healthcare providers, to patients and their families and to governments around the world. Allecra Therapeutics is situated in the BioValley Life Sciences region in the Upper Rhein valley whichencompasses northwest Switzerland, southwestern Germany and the Alsace region of France

Affectis Pharmaceuticals is a company focused on developing innovative drugs to treat neurodegenerative, neuroinflammatory, psychiatric, and inflammatory disorders. The firm utilizes research findings in the areas of depression, schizophrenia, and inflammation to discover and create new therapeutic options. Through its commitment to addressing these complex diseases, Affectis aims to advance healthcare solutions and improve patient outcomes.

Elara Pharmaceuticals Gmbh provides research and pharmaceutical development services for new anti-cancer drugs. In addition Elara Pharmaceuticals Gmbh has discovered lead series of small, bioactive molecules that have anti-tumour activity, based on inhibitors of estrogen signaling and Aurora kinases. Elara Pharmaceuticals Gmbh was founded in 2006 and is based in Heidelberg, Germany.

EndoArt is a synthetic implant that treats corneal edema by establishing a new form of corneal availability, hence protecting vision and restoring function.

vasopharm is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. In this area, the company is focused on the development of therapeutics influencing the bioavailability of nitric oxide (NO), a cellular signalling molecule involved in many physiological and pathological processes. vasopharm’s drug candidate VAS203 is an allosteric NO synthase inhibitor and represents a completely new class of modulators of nitric oxide synthase (NOS) enzymes. It rapidly lowers excessive NO production in cerebral vessels and tissues, thereby preventing life-threatening increases in intracranial pressure and associated inflammatory processes following traumatic brain injury.

Affectis Pharmaceuticals is a company focused on developing innovative drugs to treat neurodegenerative, neuroinflammatory, psychiatric, and inflammatory disorders. The firm utilizes research findings in the areas of depression, schizophrenia, and inflammation to discover and create new therapeutic options. Through its commitment to addressing these complex diseases, Affectis aims to advance healthcare solutions and improve patient outcomes.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.